Reproducible Clinical Response and Serial Electrophysiological Improvement With Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy
Clinical and Experimental Neuroimmunology · 2026-11 · 17 (4)
DOI: 10.1111/cen3.70094 ↗Abstract
ABSTRACT Background Efgartigimod has emerged as a treatment option for chronic inflammatory demyelinating polyneuropathy (CIDP); however, longitudinal electrophysiological changes during treatment and the clinical course after treatment withdrawal remain incompletely characterized. Case Presentation A woman in her 40s with CIDP showed a favorable but transient response to intravenous immunoglobulin and subsequently received subcutaneous efgartigimod as maintenance therapy. Clinical improvement was accompanied by marked electrophysiological recovery, including restoration of median sensory nerve action potentials and improvement in motor conduction parameters. After approximately 1 year of clinical stability, treatment was temporarily withdrawn, followed by clinical relapse approximately 3 weeks later. After efgartigimod reintroduction, improvement again became apparent after approximately the third administration, closely reproducing the initial treatment course. Conclusions The relapse after efgartigimod withdrawal and reproducible improvement after reintroduction support the potential role of efgartigimod as maintenance therapy in this patient. Serial nerve conduction studies may provide an objective adjunct for assessing electrophysiological response during treatment.
EUVIMED